Testing ponesimod for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis for at least 3 months.
- Your colitis symptoms are moderate to severe, including bleeding and inflammation seen on a scope.
- You have tried at least one other approved UC treatment that did not work well or caused side effects.
- You do not have Crohn's disease or another type of colitis.
- You have not taken a S1P receptor modulator (like fingolimod) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
This trial tests whether a natural compound called palmitoylethanolamide can help ulcerative colitis patients whose symptoms aren't controlled by standard medications. You'd be taking this alongside your current treatments to see if it reduces inflammation and symptoms.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.